Upcoming event

Tags

[68Ga]Ga-DPI-4452 PET/CT, 3D reconstruction, adjuvant pembrolizumab, advanced RCC, Article of the Month, Artificial intelligence, ASCO GU22, ASCO21, AUA21, augmented reality, belzutifan, biomarkers, Cabozantinib, CAIN trial, Carcinoma, CARE1 trial, ccRCC, CheckMate-214, CheckMate-9ER, Checkpoint Inhibitor, Chronic kidney disease, clampless surgery, clear cell renal cell carcinoma, Cryosurgery, cystic masses, diagnostics, durvalumab, EAU, EAU21, EAU22, EMUC2026, EMUC21, EMUC22, enucleoresection, ERUS 2026, ERUS22, ESMO21, ESMO25, expert interview, first-line, first-line treatment, Frail patient​, Glomerular filtration rate, Guidelines, histology, histotripsy, imaging, IMDC risk model, immunotherapy, International Metastatic Renal Cell Carcinoma Database Consortium, intraoperative cyst rupture, intraoperative ultrasound, Kidney cancer, kidney-preserving, Laparoscopy, lenvatinib, localised renal cell carcinoma, Lymph node metastases, Lymph nodes, Metastasectomy, metastatic clear-cell renal cell carcinoma, metastatic disease, metastatic RCC, MK-1308A, Mortality, mRCC, neoadjuvant immunotherapy, Neoplasm metastasis, Neoplasm recurrence, Nephrectomy, Nephron-sparing surgery, Nivolumab, oligometastatic renal cell carcinoma, omRCC, Overall survival, papillary tumour, Partial nephrectomy, patient reported outcomes, PD-L1+, PE-PE trial, pembrolizumab, precision therapy, Prognostication, quality of life, Radical nephrectomy, Radical surgery, RAMPART trial, RCC, Renal cancer, Renal cell, Renal cell carcinoma, Renal Cell Carcinoma guidelines, Renal cryoablation, Renal function, Renal Transplantation, Renorrhaphy, resected renal cell carcinoma, risk stratification, robot-assisted partial nephrectomy, Robotic, robotic partial nephrectomy, Robotic prostatectomy, Robotic surgery, selective clamping, stereotactic body radiation therapy, Survival outcome, Suture, sutureless partial nephrectomy, Targeted therapies, TKIs, Treatment response, tumour enucleation, tumour genomics, tumour pseudocapsule rupture, tyrosine kinase inhibitors, Urological surgery, UROonco2025, UROonco24, UROonco25, UROwebinar, Webinar, zero-ischaemia surgery
Show all

Hypertension and cardiovascular morbidity following surgery for kidney cancer

European Urology Oncology, Volume 3, Issue 2, April 2020, Pages 209-215

Topographic distribution of first landing sites of lymphatic metastases from patients with renal cancer

Urologic Oncology: Seminars and Original Investigations, Volume 38, Issue 5, May 2020, Pages 521-525

Local recurrence following resection of intermediate-high risk nonmetastatic renal cell carcinoma: an anatomical classification and analysis of the ASSURE (ECOG-ACRIN E2805) adjuvant trial

Journal of Urology, October 2020

First-line immuno-oncology combination therapies in metastatic renal-cell carcinoma: results from the international metastatic renal-cell carcinoma database consortium

European Urology, Volume 76, Issue 6, December 2020, Pages 861-867

Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC)

Nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in pretreated patients (pts) with metastatic renal cell carcinoma (mRCC): First results of phase II NIVES study

Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC)

Local recurrence following resection of intermediate-high risk nonmetastatic renal cell carcinoma: an anatomical classification and analysis of the ASSURE (ECOG-ACRIN E2805) adjuvant trial

Journal of Urology, October 2020

Cryoablation predisposes to higher cancer specific mortality relative to partial nephrectomy in patients with nonmetastatic pT1b kidney cancer

The Journal of Urology, Volume 202, Issue 6, December 2020

Nephrectomy after complete response to immune checkpoint inhibitors for metastatic Renal Cell Carcinoma (mRCC): A new surgical challenge?

The IRON study: Investigation of Robot-assisted versus Open Nephron-sparing surgery

Impact of metastasectomy on cancer specific and overall survival in metastatic renal cell carcinoma: Analysis of the REMARCC registry

PreviousNext